Market Place
Sourcing Support
BenevolentAI Announces Overhaul with Return to Original Mission
11 Dec 2024 //
BUSINESSWIRE
BenevolentAI pivots to `TechBio` roots, causing more layoffs
11 Dec 2024 //
FIERCE BIOTECH
BenevolentAI Appoints Kenneth Mulvany as Executive Chairman
17 Oct 2024 //
BUSINESSWIRE
BenevolentAI To Present At BioTechX Europe 2024
10 Oct 2024 //
BUSINESSWIRE
BenevolentAI Interim Results for the Six Months Ended 30 June 2024
19 Sep 2024 //
BUSINESSWIRE
BenevolentAI Notice of Interim Results
06 Sep 2024 //
BUSINESSWIRE
BenevolentAI: Appointment of Adviser
04 Jul 2024 //
BUSINESSWIRE
BenevolentAI: Leadership Team Change
03 Jul 2024 //
BUSINESSWIRE
BenevolentAI and AstraZeneca collaboration advances novel target into portfolio
25 Jun 2024 //
BUSINESSWIRE
BenevolentAI CEO Joins Morgan Stanley Life Sciences Summit
19 Jun 2024 //
BUSINESSWIRE
BenevolentAI: Participating At Goldman Sachs Healthcare Event
04 Jun 2024 //
BUSINESSWIRE
AstraZeneca selects new heart failure target with BenevolentAI
16 May 2024 //
PHARMACEUTICAL TECHNOLOGY
BenevolentAI Announces AstraZeneca Novel Heart Failure Target Selection Success
15 May 2024 //
BUSINESSWIRE
BenevolentAI: Result of Annual General Meeting
02 May 2024 //
BUSINESSWIRE
Shakeup at BenevolentAI continues with job, programme cuts
23 Apr 2024 //
PHARMAPHORUM
BenevolentAI Provides an Update on Its Business Priorities
22 Apr 2024 //
BUSINESSWIRE
BenevolentAI Announces Positive Topline Data from the Phase Ia Study of BEN-8744
25 Mar 2024 //
BUSINESSWIRE
BenevolentAI: Publication of 2023 Annual Report and 2024 AGM Notice
20 Mar 2024 //
BUSINESSWIRE
BenevolentAI Appoints New Chief Technology Officer
20 Mar 2024 //
BUSINESSWIRE
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2023
14 Mar 2024 //
BUSINESSWIRE
BenevolentAI: Notice of Preliminary Results
04 Mar 2024 //
BUSINESSWIRE
BenevolentAI names ex-Bayer R&D chief as new CEO
24 Jan 2024 //
FIERCE BIOTECH
BenevolentAI to present at 42nd Annual J.P. Morgan Healthcare Conference
02 Jan 2024 //
BUSINESSWIRE
BenevolentAI: Shareholder Letter December 2023
27 Dec 2023 //
BUSINESSWIRE
BenevolentAI: Directorate Change
21 Sep 2023 //
BUSINESSWIRE
BenevolentAI: Interim Results for the Six Months Ended 30 June 2023
21 Sep 2023 //
BUSINESSWIRE
Merck KGaA taps BenevolentAI, Exscientia for AI drug discovery
21 Sep 2023 //
FIERCE BIOTECH
BenevolentAI Welcomes Christina Busmalis as its New Chief Revenue Officer
18 Sep 2023 //
BUSINESSWIRE
BenevolentAI Notice of Interim Results
15 Sep 2023 //
BUSINESSWIRE
BenevolentAI: Appointment of Catherine Isted, ACMA, as Chief Financial Officer
11 Sep 2023 //
BUSINESSWIRE
BenevolentAI Doses First Participants in Clinical Trial of BEN-8744
31 Aug 2023 //
BUSINESSWIRE
BenevolentAI Progresses BEN-34712 for the Potential Treatment of ALS
04 Jun 2023 //
BUSINESSWIRE
New Preclinical Data on AI-Generated Target Identified in BenevolentAI & AZ
30 May 2023 //
BUSINESSWIRE
UK-based BenevolentAI to cut about 180 jobs as part of restructuring plan
28 May 2023 //
BUSINESS STANDARD
9xchange Joins Forces With BenevolentAI to Integrate Its AI Technology
16 May 2023 //
BUSINESSWIRE
BenevolentAI Announces Phase IIa Results for Topical pan-Trk Inhibitor BEN-2293
05 Apr 2023 //
BUSINESSWIRE
BenevolentAI flunks midphase eczema trial to dent deal plans
05 Apr 2023 //
FIERCE BIOTECH
BenevolentAI Announces Publication of Convening Notice for AGM
24 Mar 2023 //
BUSINESSWIRE
BenevolentAI Unaudited Preliminary Results for the Year Ended 31 December 2022
16 Mar 2023 //
BUSINESSWIRE
BenevolentAI: Notice of Preliminary Results
16 Feb 2023 //
BUSINESSWIRE
BenevolentAI to Present at the Cowen 43rd Annual Health Care Conference
15 Feb 2023 //
BUSINESSWIRE
As the market has turned`: Enveda secures $68M to move revised pipeline
21 Dec 2022 //
ENDPTS
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor
21 Dec 2022 //
BUSINESSWIRE
BenevolentAI to Present at 41st Annual J.P. Morgan Healthcare Conference
01 Dec 2022 //
BUSINESSWIRE
BenevolentAI to present at Jefferies Investor Conference in November
04 Nov 2022 //
BUSINESSWIRE
AstraZeneca takes home two more drug targets from BenevolentAI
07 Oct 2022 //
FIERCEBIOTECH
BenevolentAI Interim Results for the Six Months Ended 30 June 2022
27 Sep 2022 //
BUSINESSWIRE
BenevolentAI Group: Notice of Interim Results and Analyst / Investor Event
26 Aug 2022 //
PRNEWSWIRE
BenevolentAI announces participation in upcoming investor conferences
10 Jun 2022 //
PRNEWSWIRE
AstraZeneca collects 2nd lung fibrosis target from BenevolentAI
24 May 2022 //
FIERCEBIOTECH
BenevolentAI achieves third milestone in its discovery collaboration with AZ
16 May 2022 //
PRNEWSWIRE
AstraZeneca returns to BenevolentAI with new collaboration
14 Jan 2022 //
ENDPTS
BenevolentAI, AstraZeneca Expand Collaboration for SLE & heart failure
12 Jan 2022 //
PRNEWSWIRE
BenevolentAI collaborates for novel idiopathic pulmonary fibrosis target
14 Dec 2021 //
PRNEWSWIRE
Biotech star BenevolentAI floats with a £1.3bn valuation Europe’s biggest SPAC
06 Dec 2021 //
UKNEWS
BenevolentAI identifies novel target for UC & advances to IND/CTA Studies
14 Oct 2021 //
PRNEWSWIRE
Sanofi licences in potential oral IL-17 drug from UK’s C4X Discovery
12 Apr 2021 //
NEWSNOW
BenevolentAI doses first patient in atopic dermatitis drug trial
11 Feb 2021 //
CLINICALTRIALSARENA
AstraZeneca, BenevolentAI home in on computer-generated target for CKD drugs
28 Jan 2021 //
FIERCEBIOTECH
AstraZeneca picks AI-generated CKD target stemming from BenevolentAI deal
28 Jan 2021 //
FIERCE BIOTECH
